Latest Administration News

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

James Bay Minerals has entered a binding agreement to acquire the high-grade Shafter Silver Project in Texas, featuring substantial existing infrastructure and a rich production history. The acquisition is backed by a $30 million capital raise and signals a strategic expansion into a premier US mining jurisdiction.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Auric Mining has completed the acquisition of the Burbanks Gold Processing Facility for $4.4 million, positioning itself to control its gold production cycle and accelerate growth.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

MC Mining’s FY2025 results reveal a sharp increase in losses driven by impairments and lower coal sales, while a strategic investment by Kinetic Development Group advances its flagship Makhado Project.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Altamin Limited has launched a $6.46 million accelerated entitlement offer to fund exploration at its Lazio and Gorno projects, while excluding shareholders in certain jurisdictions due to regulatory constraints.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.